Clinical trial
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850 · Blue Earth Therapeutics Ltd, Industry · Recruiting
Key facts
| NCT number | NCT05413850 |
|---|---|
| Title | Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection |
| Official title | An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer |
| Lead sponsor | Blue Earth Therapeutics Ltd, Industry |
| Collaborators | PSI CRO Industry |
| Status | Recruiting |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms, Prostatic Neoplasms, Prostatic Diseases |
| Intervention type | Diagnostic Test, Drug |
| Interventions | Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only) |
| Enrollment | 82 |
| Start date | Jul 20, 2022 |
| Primary completion | Aug 27, 2026 |
| Completion | Mar 31, 2028 |
| First posted | Jun 10, 2022 |
| Last update posted | Jan 14, 2026 |
| Countries | Belgium, Netherlands, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: